Dipeptidyl peptidase 4(DPP4) inhibitors stride up the management of Parkinson's disease.
Eur J Pharmacol
; 939: 175426, 2023 Jan 15.
Article
in En
| MEDLINE
| ID: mdl-36544303
ABSTRACT
Parkinson's disease (PD) is the 2nd most common age-related hypokinetic disorder, characterized by dopaminergic degeneration and movement abnormalities. Dopaminergic degeneration in the basal ganglia is primarily seen in PD patients. The therapeutic strategies currently under investigation are to rescue dopaminergic degeneration and promote neuronal regeneration, which could halt disease progression. On the other hand, the therapeutic efficacy of existing drugs used in other disorders has been repurposed in neurodegenerative pathologies. DPP4 inhibitors widely used in treating diabetes have been considered viable target sites and are being tested for efficacy in neurodegenerative pathologies. DPP4 inhibitors have been reported to rescue neuronal degeneration and improve motor functions in various preclinical and clinical PD studies. The current review is focused on the neuroprotective potential, molecular mechanisms and therapeutic potential of DPP4 inhibitors in PD pathology.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Parkinson Disease
/
Diabetes Mellitus
/
Dipeptidyl-Peptidase IV Inhibitors
Limits:
Humans
Language:
En
Journal:
Eur J Pharmacol
Year:
2023
Document type:
Article
Affiliation country: